Answers are grounded in this paper and cite their sources.
Cardiovascular diseases remain a major cause of morbidity and mortality worldwide, with hypertension and dyslipidemia frequently occurring together and significantly increasing cardiovascular risk. Long-term management of these conditions often requires multiple medications, leading to increased pill burden and reduced patient compliance. The present study aimed to formulate and evaluate a bilayer tablet comprising an immediaterelease (IR) layer of Atorvastatin Calcium and a sustained-release (SR) layer of Nifedipine to provide combined therapeutic benefits in a single dosage form. Preformulation studies, including organoleptic evaluation, solubility studies, calibration curve preparation, and drug–excipient compatibility studies using FTIR and DSC, were performed. The immediate-release layer of Atorvastatin Calcium was formulated using suitable superdisintegrants to achieve rapid drug release, whereas the sustained-release layer of Nifedipine was developed using HPMC K100M as a release-retarding polymer to prolong drug release. Bilayer tablets were prepared by the direct compression technique and evaluated for pre-compression parameters such as angle of repose, bulk density, tapped density, Carr’s index, and Hausner ratio. Post-compression evaluation included hardness, thickness, weight variation, friability, drug content uniformity, and in vitro dissolution studies. The prepared formulations exhibited satisfactory flow properties and acceptable physicochemical characteristics. The immediate-release layer demonstrated rapid drug release, while the sustained-release layer provided prolonged release of Nifedipine over the desired period. Drug release kinetics indicated diffusion-controlled release from the sustained-release matrix. The optimized formulation showed satisfactory tablet integrity and performance characteristics. The study demonstrates that bilayer tablet technology can successfully combine immediate and sustained drug release profiles within a single dosage form. Such a formulation has the potential to improve patient compliance, reduce dosing frequency, and provide effective management of patients suffering from concurrent hypertension and dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Panpatil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: